Localized prostate cancer (PC) is curable, but options are limited for recurrent or metastatic tumors developing resistance to androgen-deprivation therapy (ADT) or AR targeted therapy (ART), known as metastatic castration-resistant prostate cancer (mCRPC). This evidence concerns the gene AR and prostate carcinoma.